glp·helper
glphelper.com/tirzepatide/california/roseville
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Roseville, CA

Verified Tirzepatide providers in Roseville, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
39
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
40 of 40 shown

Find a Tirzepatide provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /tirzepatide/california/{city}
§ 03Getting Tirzepatide in Roseville
40 providers · Roseville, CA

How to get Tirzepatide in Roseville.

40 GLP-1 prescribers and 7 local resource types are on record for Roseville, plus 3 nearby towns in the directory.

Prescribers in Roseville
40 prescribers
40 GLP-1 prescribers in Roseville, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (14), Family Medicine (12) and Internal Medicine (9). Any California-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Rocklin (33 providers), Citrus Heights (30 providers) and Lincoln (28 providers).
Around the prescription in Roseville
7 listed nearby
67 dietitians, 10 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Roseville.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Roseville

Roseville, California has a population of 147,773 people. The adult obesity rate in Roseville is an age-adjusted estimate of 27%, 2.1 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 8% of adults in Roseville. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 18.2% of adults in Roseville.

of Roseville adults have obesity
27%
diagnosed diabetes
8%
no regular physical activity
18.2%

Age-adjusted estimates for Roseville, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossGLP-1s during menopause
§ 05Support around Tirzepatide in Roseville
6 dietitians

The prescription is one part. Here is the rest, in Roseville.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Roseville, CA, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Lynea Albers, RD
RD
Registered dietitian
3100 Douglas Blvd
Call 916-774-8885NPI 1245519339
Jennifer Amirali, RD,CNSD
RD
Registered dietitian
1600 Eureka Rd
Call 916-784-4902NPI 1407912058
Jaime Aron, RD
RD
Registered dietitian
1600 Eureka Rd
Call 916-784-4532NPI 1578856795
Lori Bauer, RD
RD
Registered dietitian
4125 Temescal
Call 916-965-4012NPI 1801064613
Melissa Beck, RD
RD
Registered dietitian
6770 Stanford Ranch Rd
Call 831-251-2315NPI 1326473919
Tandis Bishop, R.D
RD
Registered dietitian
3100 Douglas Blvd
Call 916-774-8885NPI 1699141705

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Katie Callahan
NUTRITIONIST
Nutritionist
572 Gibson Dr Apt 1714
Call 916-542-3962NPI 1033051453
Paula Clayton, CN
NUTRITIONIST
Nutritionist
1431 Spring Valley Dr
Call 916-676-5197NPI 1477037927
Pamela Connor, clinical nutritionis
NUTRITIONIST
Nutritionist
1891 E Roseville Pkwy Ste 170
Call 916-404-0886NPI 1730987785
Cynthia Fairman, RD CDE
NUTRITIONIST
Nutritionist
6555 Coyle Ave
Call 916-536-3540NPI 1235268269
Nathalie Patino
NUTRITIONIST
Nutritionist · Education
301 Gibson Dr Apt 726
Call 916-217-2130NPI 1720832116
Paulette Perfumo, PhD
NUTRITIONIST
Nutritionist
413 Hearthstone Ct
Call 707-580-1589NPI 1487012712
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in California

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]